SpliSense is a company developing transformative RNA-based treatments for unmet needs relating to Cystic Fibrosis (CF) and diverse pulmonary diseases. Our treatment is based on clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation to the lungs.
We are focused on a variety of innovative therapies, in different development stages from discovery to IND.